Impressive results from the trial on PCKS9 inhibitors include a 59% reduction in LDL cholesterol and 25% reduction in CV death, MI, and stroke, with new findings on safety. Is the high cost sustainable, and what will the longer, ongoing ODYSSEY trial show?